INTELLIGENT PEPTIDE DISCOVERY

Unique Artificial Intelligence for groundbreaking drug discovery

WHO WE ARE

Pepticom Ltd. was founded in 2011 aimed at revolutionizing the discovery of novel peptide-drug candicates. Pepticom’s key asset is a unique Artificial Intelligence platform for peptide design based on the target's solved crystal structure. Pepticom operates in various markets, generating innovative binding peptides for diverse targets. Past successful discoveries include active molecules in Metabolic diseases, Alzheimer's disease and as Immuno-modulators. Read more about Pepticom Ltd. in the About section.